Aspirin as adjuvant therapy for colorectal cancer: A promising new twist for an old drug

JAMA

Volumn 302, Issue 6, 2009, Pages 688-689

  Neugut, Alfred I ^a,b,c  

^a College of Physicians and Surgeons ^*  (United States)

^b Columbia University ^*  (United States)

^c NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; B RAF KINASE; CELECOXIB; CETUXIMAB; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONE RECEPTOR; PANITUMUMAB; PLACEBO; ROFECOXIB; TRASTUZUMAB; ANTINEOPLASTIC AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR; TUMOR MARKER;

ADJUVANT THERAPY; BLEEDING; BREAST CANCER; CANCER MORTALITY; CANCER SURVIVAL; CARDIOTOXICITY; COLORECTAL CANCER; EDITORIAL; GASTROINTESTINAL IRRITATION; GENE MUTATION; GENE OVEREXPRESSION; HORMONAL THERAPY; HUMAN; KIRSTEN SARCOMA ONCOVIRUS; PRIORITY JOURNAL; ADJUVANT CHEMOTHERAPY; CANCER STAGING; COLORECTAL TUMOR; GENE EXPRESSION REGULATION; LIFESTYLE; METABOLISM; MORTALITY; NOTE; PATHOLOGY; UPREGULATION;

ANTINEOPLASTIC AGENTS; ASPIRIN; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIFE STYLE; NEOPLASM STAGING; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 68849122271     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2009.1145     Document Type: Editorial

References (24)

1. Vonkeman HE, van de Laar MA. Nonsteroidal anti-inflammatory drugs: adverse effects and their prevention [published online ahead of print September 27, 2008]. Semin Arthritis Rheum. doi:10.1016/j.semarthrit.2008.08.001.
2. Sporn MB, Dunlop NM, Newton DL, Smith JM. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc. 1976; 35(6):1332-1338.
3. Cuzick J, Otto F, Baron JA, et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol. 2009;10(5):501-507.
4. Ogino S, Kirkner GJ, Nosho K, et al. Cyclooxygenase-2 expression is an independent predictor of poor prognosis in colon cancer. Clin Cancer Res. 2008; 14(24):8221-8227.
5. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 1994;107(4):1183-1188.
6. Dubé C, Rostom A, Lewin G, et al; US Preventive Services Task Force. The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the US Preventive Services Task Force. Ann Intern Med. 2007;146 (5):365-375.
7. Bertagnolli MM, Eagle CJ, Zauber AG, et al; APC Study Investigators. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med. 2006; 355(9):873-884.
8. Arber N, Eagle CJ, Spicak J, et al; PreSAP Trial Investigators. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med. 2006;355(9): 885-895.
9. Solomon SD, Wittes J, Finn PV, et al; Cross Trial Safety Assessment Group. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation. 2008;117(16):2104-2113.
10. Baron JA, Sandler RS, Bresalier RS, et al; APPROVe Trial Investigators. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology. 2006;131(6):1674-1682.
11. Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA. 2009;302(6):649-659.
12. Fuchs CS, Meyerhardt JA, Heseltine DS, et al. Influence of regular aspirin use on survival for patients with stage III colon cancer: findings from Intergroup Trial CALGB 89803. J Clin Oncol. 2005;23(16s):3530.
13. Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol. 2007; 25(30):4779-4786.
14. Solomon SD, McMurray JJ, Pfeffer MA, et al; Adenoma Prevention with Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005;352(11): 1071-1080.
15. Fuchs C, Marshall J, Mitchell E, et al. Updated results of BICC-C study comparing first-line irinotecan/fluoropyrimidine combinations with or without celecoxib in mCRC: updated efficacy data. J Clin Oncol. 2007;25(18S):4027.
16. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359(17): 1757-1765.
17. Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol. 2008;26(35):5705-5712.
18. Neugut AI. Preventive oncology-lessons from preventive cardiology. Lancet. 2004;363(9414):1004-1005.
19. Meyerhardt JA, Niedzwiecki D, Hollis D, et al. Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer. JAMA. 2007;298(7):754-764.
20. Meyerhardt JA, Giovannucci EL, Holmes MD, et al. Physical activity and survival after colorectal cancer diagnosis. J Clin Oncol. 2006;24(22):3527-3534.
21. Meyerhardt JA, Heseltine D, Niedzwiecki D, et al. Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J Clin Oncol. 2006;24(22):3535-3541.
22. Meyerhardt JA, Niedzwiecki D, Hollis D, et al; Cancer and Leukemia Group B 89803. Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemia Group B 89803. J Clin Oncol. 2008;26(25):4109-4115.
23. Meyerhardt JA, Tepper JE, Niedzwiecki D, et al. Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114. J Clin Oncol. 2004;22(4):648-657.
24. Jackson NA, Fuchs CS, Niedzwiecki D, et al. The impact of smoking on cancer recurrence and survival in patients with stage III colon cancer: findings from intergroup trial CALGB 89803. J Clin Oncol. 2008;26(15s):4039.